Montreal, Quebec. June 25, 2008 – MethylGene Inc. (TSX: MYG) announced today the initiation of a Phase II clinical trial (Trial 013) evaluating MGCD0103, an isoform-selective histone deacetylase (HDAC) inhibitor product candidate, in combination with Vidaza(R) (azacitidine for injection), a DNA demethylating agent, in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).
Methylgene announces the initiation of a Phase 2 trial of MGCD0103
Plexxikon announces preclinical data demonstrating dramatic improvement in key symptoms of polycystic kidney disease
BERKELEY, Calif., May 21, 2008 --(BUSINESS WIRE)-- Plexxikon Inc. today announced data from preclinical studies of Polycystic Kidney Disease (PKD) demonstrating significantly reduced kidney disease following treatment with Plexxikon’s novel drug candidate. Plexxikon’s novel small molecule kinase inhibitor is a highly selective and potent inhibitor of Raf kinase, a critical mediator of PKD pathology. These data were recently presented at the ISN Forefronts Symposium on Polycystic Kidney Disease in Montreal, Canada by Stefan Somlo, M.D., CNH Long Professor of Internal Medicine and Genetics and Chief of Nephrology at the Yale University School of Medicine.
Dynogen presents results of its positive Phase 2 IBS-d study with DDP225
WALTHAM, Mass.--(BUSINESS WIRE)--May 20, 2008 - Dynogen Pharmaceuticals, Inc. announced today the presentation of positive results from its Phase 2a trial of DDP225 in patients with irritable bowel syndrome with diarrhea (IBS-d) at the Digestive Disease Week 2008 (DDW) scientific meeting. The randomized, double-blind, placebo controlled trial established clinical proof-of-concept with statistically significant results for the endpoint of relief of abdominal pain or discomfort associated with IBS-d. Dynogen previously reported top-line results from this Phase 2a trial in December 2007. The DDW abstract was co-authored by Dynogen and a team of investigators from leading clinical centers in Canada. The DDP225 results were presented yesterday in a Distinguished Abstract Plenary session on Neurogastroenterology and Motility by Steven B. Landau, M.D., a member of Dynogen’s Scientific Advisory Board.
Genstruct and Sirtris Pharmaceuticals win Bio-IT World's Best Practices Award
CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology, today announced that its joint collaboration with Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, has won Bio-IT World magazine’s 2008 Best Practices Award in the Drug Discovery & Development category. The project was focused on discovering mechanisms of action (MOA) for Type 2 diabetes.
BrainCells Inc. initiates Phase 2 clinical trial with BCI-540 for depression with anxiety
SAN DIEGO, April 17, 2008 – BrainCells Inc. (BCI), a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced today that it has initiated a Phase 2a clinical trial with its lead product candidate, BCI-540, for the treatment of depression with anxiety.
BrainCells expands Series B financing to $50 million
San Diego, CA, April 17, 2008 – BrainCells Inc. (BCI), a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced today that it raised an additional $20 million in an extension of its Series B financing, bringing the total to $50 million. New investor, New Enterprise Associates (NEA), along with current investors and Alexandria Real Estate Equities, Inc. participated in the extension. Other investors that participated in the Series B included MedImmune Ventures, Bay City Capital, Oxford Bioscience Partners, Technology Partners, Pappas Ventures and NeuroVentures. The financing will be used to continue clinical development of BCI’s product candidates including a Phase 2 trial with BCI-540, and to identify additional assets to further expand its pipeline.
DSMB supports continuation of Anthera Phase 2 impacts trial for the prevention of acute chest syndrome in patients with sickle cell disease
SAN MATEO, CA – April 16, 2008 – Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera’s Phase II clinical trial, known as the IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) Study can continue under the current protocol, without change.
Bayhill Therapeutics presents data from a Phase 2 trial of BHT-3009 in multiple sclerosis at American Academy of Neurology 60th annual meeting
PALO ALTO, Calif., April 16, 2008 - (BUSINESS WIRE) - Bayhill Therapeutics, Inc. today announced that the Company’s co-founder and Vice President of Research, Hideki Garren, M.D., Ph.D., gave a podium presentation at the American Academy of Neurology 60th Annual Meeting (AAN) in Chicago. Dr. Garren’s presentation, “Results from a Phase II Trial of a Myelin Basic Protein Encoding DNA Vaccine for Relapsing Multiple Sclerosis," provides further analysis of data from a Phase II study evaluating BHT-3009, a tolerizing DNA vaccine for multiple sclerosis (MS).
MethylGene initiates Phase 1 clinical trial for its multi-targeted (c-Met) kinase inhibitor, MGCD265, in solid tumor cancers
MGCD265 Targets c-Met, VEGFs, Tie-2 and Ron Receptor Tyrosine Kinases
Initial Compound from Portfolio of Potent Multi-targeted Kinase Inhibitors
Montreal, Quebec. April 16, 2008 – MethylGene Inc. (TSX:MYG) today disclosed preclinical data for MGCD265, an oral, multi-targeted (c-Met) kinase inhibitor for cancer that targets the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. The data were presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting in San Diego.
LipoScience: LDL particle measurement by NMR recognized in consensus statement by the ADA and the ACC
RALEIGH, N.C., March 28 /PRNewswire/ -- The American Diabetes Association (ADA) and the American College of Cardiology (ACC) issued a consensus statement today that states the measurement of LDL particle number by nuclear magnetic resonance (NMR) is one of the more accurate ways to evaluate cardiometabolic risk (CMR). The study, published in the April issue of Diabetes Care, reinforces that LDL cholesterol may not be the best way to quantify a patient’s risk for cardiovascular disease (CVD).
